The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
FOXO1 is a tumor suppressor in classical Hodgkin lymphoma
Open accessAbstract
The FOXO transcription factors control proliferation and apoptosis in different cell types. Their activity is regulated by posttranslational modifications, mainly by the PI3K-PKB pathway, which controls nuclear export and degradation. We show that FOXO1 is highly expressed in normal germinal center B cells as well as in non-Hodgkin lymphomas, including follicular lymphoma, diffuse large B-cell lymphoma, mucosa-associated lymphoid tissue non-Hodgkin lymphoma, B-cell chronic lymphocytic leukemia, and mantle cell lymphoma. In contrast, in 31 of 32 classical Hodgkin lymphoma (cHL) cases, Hodgkin and Reed-Sternberg cells were FOXO1 negative. Neoplastic cells of nodular lymphocyte-predominant Hodgkin lymphoma were negative in 14 of 20 cases. FOXO1 was down-regulated in cHL cell lines, whereas it was expressed in non-Hodgkin lymphoma cell lines at levels comparable with normal B cells. Ectopic expression of a constitutively active FOXO1 induced apoptosis in cHL cell lines and blocked proliferation, accompanied with cell-cycle arrest in the G0/G1 phase. We found that, in cHL cell lines, FOXO1 is inactivated by multiple mechanisms, including constitutive activation of AKT/PKB and MAPK/ERK kinases and up-regulation of microRNAs miR-96, miR-182, and miR-183. These results suggest that FOXO1 repression contributes to cHL lymphomagenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calnan, D. R., & Brunet, A. (2008) · Oncogene · doi:10.1038/onc.2008.21 · Cited by 1,170
IκB Kinase Promotes Tumorigenesis through Inhibition of Forkhead FOXO3a
Hu, M. C.-T., Lee, D.-F., Xia, W., Golfman, L. S., Ou-Yang, F., Yang, J.-Y., Zou, Y., Bao, S., Hanada, N., Saso, H., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00302-2 · Cited by 868
Cited by
Redox regulation of FoxO transcription factors
Klotz, L.-O., Sánchez-Ramos, C., Prieto-Arroyo, I., Urbánek, P., Steinbrenner, H., & Monsalve, M. (2015) · Redox Biology · doi:10.1016/j.redox.2015.06.019 · Cited by 747
FOXO Signaling Pathways as Therapeutic Targets in Cancer
Farhan, M., Wang, H., Gaur, U., Little, P. J., Xu, J., & Zheng, W. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.20052 · Cited by 533
MicroRNAome genome: A treasure for cancer diagnosis and therapy
Berindan‐Neagoe, I., Monroig, P. D. C., Pasculli, B., & Calin, G. A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21244 · Cited by 522
WBSMDA: Within and Between Score for MiRNA-Disease Association prediction
Chen, X., Yan, C. C., Zhang, X., You, Z.-H., Deng, L., Liu, Y., Zhang, Y., & Dai, Q. (2016) · Scientific Reports · doi:10.1038/srep21106 · Cited by 376
Sequence-based design of bioactive small molecules that target precursor microRNAs
Velagapudi, S. P., Gallo, S. M., & Disney, M. D. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1452 · Cited by 327
Metadata
- Authors
- Xie, L., Ushmorov, A., Leithäuser, F., Guan, H., Steidl, C., Färbinger, J., Pelzer, C., Vogel, M. J., Maier, H. J., Gascoyne, R. D., Möller, P., & Wirth, T.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2012-04-12
- Volume
- 119
- Issue
- 15
- Pages
- 3503-3511
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2072009397
- Cited by
- 171
- References
- 2
- FWCI
- 6.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FOXO1 is a tumor suppressor in classical Hodgkin lymphoma. https://app.cochat.ai/papers/10.1182/blood-2011-09-381905
- The paper
- Xie, L., Ushmorov, A., Leithäuser, F., Guan, H., Steidl, C., Färbinger, J., Pelzer, C., Vogel, M. J., Maier, H. J., Gascoyne, R. D., Möller, P., & Wirth, T. (2012). FOXO1 is a tumor suppressor in classical Hodgkin lymphoma. Blood. https://doi.org/10.1182/blood-2011-09-381905
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.